HC Wainwright Issues Pessimistic Estimate for MAZE Earnings

Maze Therapeutics, Inc. (NASDAQ:MAZE) – Analysts at HC Wainwright cut their Q2 2026 earnings estimates for Maze Therapeutics in a note issued to investors on Wednesday, May 20th. HC Wainwright analyst A. Ghosh now expects that the company will post earnings of ($0.82) per share for the quarter, down from their previous forecast of ($0.65). HC Wainwright currently has a “Buy” rating and a $110.00 price objective on the stock. The consensus estimate for Maze Therapeutics’ current full-year earnings is ($2.65) per share. HC Wainwright also issued estimates for Maze Therapeutics’ Q3 2026 earnings at ($0.87) EPS, Q4 2026 earnings at ($0.82) EPS, FY2026 earnings at ($2.96) EPS, FY2027 earnings at ($3.51) EPS, FY2028 earnings at ($3.08) EPS, FY2029 earnings at ($2.60) EPS and FY2030 earnings at ($0.74) EPS.

Several other brokerages have also recently issued reports on MAZE. Wedbush lifted their price objective on Maze Therapeutics from $43.00 to $58.00 and gave the company an “outperform” rating in a research note on Monday, March 16th. Guggenheim raised their target price on shares of Maze Therapeutics from $46.00 to $58.00 and gave the company a “buy” rating in a report on Wednesday, March 4th. Weiss Ratings reiterated a “sell (d)” rating on shares of Maze Therapeutics in a research note on Thursday, January 22nd. Mizuho upgraded shares of Maze Therapeutics to a “strong-buy” rating in a report on Wednesday, March 11th. Finally, Wall Street Zen raised shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Two analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Maze Therapeutics currently has an average rating of “Buy” and an average price target of $66.00.

Maze Therapeutics Trading Up 2.9%

MAZE opened at $25.75 on Friday. The business has a fifty day moving average price of $31.68 and a 200 day moving average price of $37.76. The company has a debt-to-equity ratio of 0.11, a current ratio of 17.88 and a quick ratio of 17.88. Maze Therapeutics has a 12 month low of $9.73 and a 12 month high of $53.65. The stock has a market capitalization of $1.43 billion, a price-to-earnings ratio of -10.18 and a beta of 2.50.

Maze Therapeutics (NASDAQ:MAZE) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.02). The firm had revenue of $20.00 million during the quarter.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Washington University lifted its position in Maze Therapeutics by 33.3% in the fourth quarter. Washington University now owns 280,802 shares of the company’s stock valued at $11,634,000 after acquiring an additional 70,121 shares during the last quarter. Mass General Brigham Inc purchased a new position in shares of Maze Therapeutics during the fourth quarter worth about $9,943,000. ArrowMark Colorado Holdings LLC purchased a new position in shares of Maze Therapeutics during the third quarter worth about $14,135,000. Boothbay Fund Management LLC increased its position in shares of Maze Therapeutics by 365.9% during the third quarter. Boothbay Fund Management LLC now owns 351,875 shares of the company’s stock worth $9,124,000 after purchasing an additional 276,345 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in shares of Maze Therapeutics by 27.1% during the fourth quarter. Vanguard Group Inc. now owns 1,697,015 shares of the company’s stock worth $70,307,000 after purchasing an additional 362,060 shares in the last quarter.

Insiders Place Their Bets

In other Maze Therapeutics news, CEO Jason V. Coloma sold 1,938 shares of the stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $26.00, for a total value of $50,388.00. Following the transaction, the chief executive officer directly owned 31,001 shares in the company, valued at $806,026. This represents a 5.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Harold Bernstein sold 15,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 14th. The stock was sold at an average price of $26.22, for a total transaction of $393,300.00. Following the sale, the chief marketing officer directly owned 15,000 shares in the company, valued at approximately $393,300. The trade was a 50.00% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 86,938 shares of company stock worth $3,399,463 over the last 90 days. Insiders own 5.30% of the company’s stock.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical?stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de?risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.